Welcome to the Ivabradine in Heart Failure with Reduced Ejection Fraction Pre Activity assessment.
Thank you and congratulations for attending this educational activity. Remember, continuous professional development is key to success and professional excellence.
Ivabradine in HF pre
0 of 6 Questions completed
You have already completed the quiz before. Hence you can not start it again.
Quiz is loading…
You must sign in or sign up to start the quiz.
You must first complete the following:
0 of 6 Questions answered correctly
Time has elapsed
You have reached 0 of 0 point(s), (0)
Earned Point(s): 0 of 0, (0)
0 Essay(s) Pending (Possible Point(s): 0)
- Not categorized 0%
Thank you for taking part in this educational activity. Please make sure you filled the Survey from the link above
Question 1 of 6
1. Question1 point(s)
Prevalence of HF and LV dysfunction decreasing steeply with ageCorrectIncorrect
Question 2 of 6
2. Question1 point(s)
Obesity and diabetes are considered risk factors for HFCorrectIncorrect
Question 3 of 6
3. Question1 point(s)
Which of the following HF treatment is approved to increase survivalCorrectIncorrect
Question 4 of 6
4. Question1 point(s)
Ivabradine should be used in patient with Sinoatrial block or third-degree AV blockCorrectIncorrect
Question 5 of 6
5. Question1 point(s)
In the SHIFT trial: Ivabradine reduced CV mortality or heart failure hospitalization by 18% (p<0.0001)CorrectIncorrect
Question 6 of 6
6. Question1 point(s)
The overall results of the primary endpoints (composite of cardiovascular death, admission to hospital for acute myocardial infarction, and admission to hospital for new onset or worsening heart failure) were significant in the Beautiful trialCorrectIncorrect